Authored By: Fatema Bandukwala
AKK New Law Academy, Pune
1. Case Citation and Basic Information
Full Case Name: Gard and Others v. The United Kingdom
Application No.: 39793/17
Court: European Court of Human Rights (First Section); preceded by proceedings before the UK High Court, Court of Appeal, and UK Supreme Court
Date of Decision: 27 June 2017 (ECtHR Decision on Admissibility); 8 June 2017 (UK Supreme Court)
Bench Composition: UK Supreme Court: President Lady Hale and Lords Kerr, Wilson, Hodge, and Lady Black. ECtHR First Section: President Sicilianos and six judges.
Key Domestic Judges: Mr Justice Francis (High Court); Lady Justice King (Court of Appeal)
2. Introduction
The case of Gard and Others v. The United Kingdom is a landmark legal proceeding at the intersection of medical ethics, parental rights, and fundamental human rights. It arose from the tragic circumstances of Charles (Charlie) Gard, a British infant born in August 2016 who suffered from a rare and fatal genetic condition. The case raised profound questions about the respective roles of parents, medical professionals, and courts in making end-of-life decisions for children who cannot speak for themselves.
The proceedings traversed the entire hierarchy of the United Kingdom’s judicial system from the High Court through the Court of Appeal and the UK Supreme Court before arriving at the European Court of Human Rights (ECtHR). At its core, the case forced courts to weigh the right to life under Article 2, the prohibition on inhuman treatment under Article 3, the right to liberty under Article 5, and the right to family life under Article 8 of the European Convention on Human Rights (ECHR).
The case carries enduring importance as a touchstone for how liberal democracies navigate the competing claims of parental autonomy, a child’s best interests, and the limits of medical intervention. It also set a significant precedent on the standing of parents to bring human rights claims on behalf of incapacitated children.
3. Facts of the Case
Charlie Gard was born on 4 August 2016 to Connie Yates and Chris Gard. He initially appeared healthy but soon developed progressive and severe health complications. He was diagnosed with infantile onset encephalomyopathic mitochondrial DNA depletion syndrome (MDDS), a rare genetic disorder caused by mutations in the RRM2B gene. The condition affected Charlie’s brain function, muscular development, and respiratory capacity though his heart, liver, and kidneys were only mildly affected.
By October 2016, Charlie had been admitted to Great Ormond Street Hospital (GOSH) in London, where he was placed on artificial ventilation. Medical experts at GOSH concluded that the condition was progressive and fatal, that there was no proven treatment, and that continued artificial ventilation was causing Charlie ongoing pain and suffering without any prospect of improvement.
In early 2017, Charlie’s parents became aware of an experimental nucleoside therapy being researched in the United States by Dr Michio Hirano of Columbia University. They raised funds through a public campaign to take Charlie to America for the treatment. GOSH declined to agree to this course of action, taking the view that the treatment was unproven and that undergoing it would not be in Charlie’s best interests, that it would merely prolong his suffering.
Unable to resolve the dispute, GOSH applied to the High Court of England and Wales for a declaration that it would be lawful to withdraw life-sustaining treatment from Charlie and to allow him to die with dignity, in accordance with medical opinion. Charlie’s parents opposed the application, insisting on their right as parents to seek experimental treatment for their child and arguing that any chance of improvement, however small, must be pursued.
The High Court, Court of Appeal, and UK Supreme Court each upheld the hospital’s position. The Supreme Court rejected the parents’ appeal on 8 June 2017. The parents then lodged an application with the ECtHR, which issued an interim measure initially requiring Charlie to be kept alive, before ultimately declaring the application inadmissible on 27 June 2017. Charlie Gard passed away on 28 July 2017, shortly after life support was withdrawn.
4. Legal Issues
The courts were asked to consider the following key questions of law:
Whether it was lawful for GOSH to withdraw life-sustaining treatment (artificial ventilation and nutrition) from Charlie against his parents’ wishes, in the context of a fatal and progressive illness.
Whether the ‘best interests of the child’ standard, as applied by the domestic courts, was compatible with the right to life under Article 2 ECHR and the right to private and family life under Article 8 ECHR.
Whether the parents had standing to bring human rights complaints before the ECtHR on behalf of their son, given a potential conflict of interest between the parents’ wishes and the child’s legally-determined best interests.
Whether the domestic legal framework governing access to experimental medical treatment for terminally ill patients was compatible with Article 2 ECHR.
Whether the decisions of the UK courts, particularly on the question of experimental therapy amounted to a violation of the parents’ rights under Article 8 (right to respect for private and family life).
Whether Charlie’s continued hospitalisation amounted to a deprivation of liberty in violation of Article 5 ECHR.
5. Arguments Presented
5.1 Petitioner/Appellant’s Arguments (Charlie’s Parents)
The parents advanced several powerful contentions throughout the litigation:
As persons with parental responsibility, they had the right and the duty to seek any available treatment for their child. The State had no justification for overriding that parental authority absent proof that the parents were acting in bad faith or causing direct harm.
The ‘best interests’ test, as applied, was overly paternalistic. Where experimental treatment offered even a minimal chance of improving Charlie’s condition, the presumption in favour of life should prevail.
They relied on Article 2 ECHR, arguing that the State’s positive obligation to protect life required it to facilitate access to the nucleoside therapy in the United States, which they had privately funded.
Under Article 8, they argued that the court orders preventing them from taking Charlie abroad amounted to a disproportionate and unlawful interference with their right to respect for private and family life.
They contended that the Court of Appeal erred procedurally by refusing to hear witness evidence from Dr Hirano, raising concerns under Article 6 (right to a fair trial).
They argued that Charlie’s continued detention in the hospital contrary to their wishes as his legal guardians amounted to a violation of Article 5.
5.2 Respondent’s Arguments (Great Ormond Street Hospital / UK Government)
GOSH contended that its primary legal and ethical duty was to the patient, Charlie and that this duty required it to act in his best interests, which was a matter for independent judicial determination, not parental preference.
Medical experts including the expert nominated by the parents’ choice concluded that the nucleoside therapy would not benefit a patient with Charlie’s specific strain of RRM2B-related MDDS. The treatment had not reached experimental stage even in animal models for this specific mutation.
Withdrawing artificial ventilation was in Charlie’s best interests because continued treatment was prolonging his suffering, with no realistic prospect of improvement. The presumption in favour of life-prolonging treatment had been rebutted by the extensive medical evidence.
The domestic legal framework, including the Children Act 1989 and the inherent jurisdiction of the High Court provided a robust and Convention-compatible mechanism for resolving such disputes. Courts were empowered and required to act as an independent arbiter of the child’s best interests.
Before the ECtHR, the UK government maintained that domestic courts had applied the ‘best interests’ standard in full compliance with the requirements of Articles 2 and 8 ECHR, and that there was no positive obligation under Article 2 to mandate access to unproven, experimental treatments.
6. Court’s Reasoning and Analysis
High Court (Mr Justice Francis)
Mr Justice Francis applied the ‘best interests’ test in its widest sense, going beyond purely medical considerations to include social, psychological, and emotional welfare. He acknowledged the strong legal presumption in favour of life-preserving treatment, a presumption derived from established authorities including Airedale NHS Trust v Bland [1993] and NHS Trust v MB [2006] but found that it had been rebutted on the specific facts.
The judge emphasised that the experimental nucleoside therapy had not been tried on any patient with Charlie’s particular genetic mutation and had not even been tested on mice with this strain of MDDS. The consensus of all medical experts, including those instructed by the parents, was that the treatment would be futile and that Charlie was likely experiencing significant and ongoing pain and distress.
Court of Appeal and UK Supreme Court
Both appellate courts declined to interfere with the High Court’s assessment of the medical evidence. The UK Supreme Court, in its brief order of 8 June 2017, dismissed the parents’ appeal, endorsing the lower court’s approach and finding no arguable error of law. The court reiterated that the ‘best interests’ standard required decision-makers to consider welfare in the widest sense, medical, social, psychological and that courts, not parents, exercised ultimate jurisdiction in such cases where disputes reached litigation.
European Court of Human Rights
The ECtHR declared the application inadmissible on 27 June 2017. On the question of standing, applying the two-part test from Lambert and Others v France (2015), the Court held that Charlie’s parents could not bring claims on Charlie’s behalf because a conflict of interest existed the domestic courts had found that the parents’ wishes were not in Charlie’s best interests, even though he had never expressed his own views or lived independently. The Court noted that Charlie’s guardian had been actively involved in the proceedings and was available to represent him before the ECtHR.
On the substance of Articles 2 and 8, applying the ‘wide margin of appreciation’ afforded to states in matters of sensitive moral and ethical judgment, the ECtHR found that the domestic legal framework was compatible with the Convention. It held that Article 2 does not require states to legislate for access to unapproved, experimental treatments for terminally ill patients. The interference with the parents’ Article 8 rights was found to be lawful, proportionate, and in pursuit of the legitimate aim of protecting the health and rights of a minor.
7. Judgment and Ratio Decidendi
High Court: Declared that it was lawful for GOSH to withdraw artificial ventilation and to provide palliative care only. The hospital was not required to facilitate travel to the United States for experimental treatment.
Court of Appeal and Supreme Court: Dismissed the parents’ appeal, upholding the High Court’s decision.
ECtHR: Declared the application inadmissible; the decision was final.
Ratio Decidendi: The binding legal principle, the ratio decidendi, established by the case may be summarised as follows: where a dispute arises between parents and treating physicians regarding the withdrawal of life-sustaining treatment from a child who lacks capacity, the court exercises independent and ultimate jurisdiction over the child’s best interests. The best interests test applies in its widest sense, encompassing medical, psychological, social, and emotional considerations. The strong legal presumption in favour of life-preserving treatment may be rebutted where extensive medical evidence establishes that continued treatment is futile and causes the child ongoing harm. In such circumstances, a court-sanctioned decision to withdraw treatment does not violate Articles 2 or 8 of the ECHR, provided the domestic legal framework affords adequate procedural safeguards.
In addition, the ECtHR’s admissibility decision established a significant procedural principle: parents do not automatically have standing to bring human rights claims before the Court on behalf of their child where the domestic courts have found a conflict of interest between the parents’ wishes and the child’s legally determined best interests.
8. Critical Analysis
(1) Significance of the Decision
The Charlie Gard case is one of the most significant end-of-life cases in British legal history, both for the intensity of public attention it attracted and for the clarity with which it resolved a series of difficult constitutional and ethical questions. It reaffirmed that courts and not parents, and not the State, are the final arbiters of a child’s best interests when disputes over medical treatment reach litigation.
The decision confirmed the enduring vitality of the ‘best interests’ standard as articulated in Airedale NHS Trust v Bland and subsequent cases, while extending it to the specific context of experimental treatment for terminally ill infants. It also confirmed that there is no positive obligation under Article 2 ECHR on states to mandate access to unproven experimental therapies.
(2) Implications and Impact
The case has had a lasting impact on several areas of law and practice:
Medical law: It provided important guidance on the threshold for rebutting the presumption in favour of life-sustaining treatment, and confirmed that judicial oversight of treatment disputes is compatible with the ECHR. It has been frequently cited in subsequent cases concerning the withdrawal of treatment from incapacitated patients.
Parental rights: The case drew a clear boundary around the scope of parental authority in medical decision-making, confirming that parental rights are not absolute and are subject to judicial control where they conflict with the child’s best interests.
Access to experimental treatment: The ECtHR’s ruling that Article 2 does not require states to provide access to unapproved therapies has implications for the ongoing legal and ethical debate around ‘right to try’ legislation in multiple jurisdictions.
Standing before the ECtHR: The decision’s procedural holding on standing that parents cannot automatically bring claims on behalf of a child where a conflict of interest existsis an important clarification of ECtHR procedure in cases involving vulnerable individuals.
(3) Critical Evaluation
The judgment, while legally coherent, has attracted criticism from several perspectives. Some commentators have argued that the courts placed excessive weight on medical consensus and insufficient weight on the parents’ fundamental right to seek any available treatment for their child. The case was widely characterised, particularly in the American press as an example of state overreach, and it prompted renewed debate in the United States over ‘right to try’ legislation.
A further critique relates to the procedural decision of the Court of Appeal not to hear oral evidence from Dr Hirano. Although this did not, in the view of the domestic courts, affect the outcome, given the strength of the medical consensus it left open a sense that the parents were denied a full opportunity to test the medical evidence adversarially.
On the other hand, supporters of the decision argue that the courts performed exactly the function they were designed for: providing an independent, expert, and impartial assessment of the child’s welfare, free from the understandable but potentially distorting influence of parental grief and hope. The appointment of an independent guardian for Charlie, who participated actively in all proceedings, was a crucial safeguard ensuring that the child’s interests were separately and independently represented.
The case also illustrates the tensions inherent in the relationship between the UK Supreme Court and the ECtHR. Critics have noted that the Supreme Court’s dismissal of the appeal was unusually brief, given the gravity of the issues at stake, and that greater engagement with the substantive human rights arguments by the UK’s apex court would have been desirable particularly on the question of whether the withdrawal of treatment was consistent with Article 2.
9. Conclusion
The Charlie Gard case stands as a watershed moment in the development of medical law and human rights jurisprudence in the United Kingdom. It confirmed the primacy of the ‘best interests of the child’ standard, defined in its widest sense, as the governing principle in disputes between parents and medical professionals over the treatment of incapacitated children. It established that the positive obligation to protect life under Article 2 ECHR does not require states to facilitate access to experimental treatments that medical evidence identifies as futile and harmful. It clarified the limits of parental authority and the scope of standing before the ECtHR in cases involving vulnerable individuals.
At a deeper level, the case reflects the profound ethical challenges facing modern medicine and law as medical technology creates possibilities that outpace established legal and moral frameworks. The tragedy of Charlie Gard’s short life gave rise to legal proceedings that, despite their sorrow, have left behind a body of doctrine that will guide courts, doctors, and families in similarly difficult situations for many years to come.
10. Reference(S):
Cases
Gard and Others v. The United Kingdom, Application No. 39793/17, ECtHR (First Section), 27 June 2017
Great Ormond Street Hospital v Yates and Others [2017] EWHC 972 (Fam) (Mr Justice Francis, 11 April 2017)
Yates and Gard v Great Ormond Street Hospital [2017] EWCA Civ 410 (23 May 2017)
Yates and Gard v Great Ormond Street Hospital [2017] UKSC 24 (8 June 2017)
Airedale NHS Trust v Bland [1993] AC 789 (House of Lords)
Lambert and Others v France, Application No. 46043/14, ECtHR Grand Chamber, 5 June 2015
Glass v United Kingdom, Application No. 61827/00, ECtHR, 9 March 2004
Re A (Children) (Conjoined Twins: Medical Treatment) [2001] Fam 147 (Court of Appeal)
Statutes and Conventions
Human Rights Act 1998 (UK)
Children Act 1989 (UK), s. 1
European Convention on Human Rights, Articles 2, 5, 6, 8
Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine (Oviedo Convention), 1997
Secondary Sources
Dominic Wilkinson and Julian Savulescu, ‘Gard Case: Why Did Charlie Die?’ (2018) 391 The Lancet 1173
Christopher Stone, ‘Legal Precedent and the Charlie Gard Case’ (2017) 44 Journal of Medical Ethics 701
Stephanie Burn, ‘Gard and Others v UK: Passive Euthanasia and the Limits of Parental Authority’ (2017) International Law Blog <https://internationallaw.blog>
Human Rights Law Centre, ‘The Charlie Gard Case: UK High Court Rules Against Experimental Medical Treatment’ (2017) <https://hrlc.org.au>
